||Recombinant Human Fas Ligand MS Standard Protein, C13 and N15-labeled (Fas Ligand, Heavy Labeled) Pro 134 - Leu 281 (Accession # AAH17502.1) was produced in human 293 cells (HEK293).
||Fas ligand also known as FasL, CD178, CD95L, or TNFSF6, is a homotrimeric type-II transmembrane protein that belongs to the tumor necrosis factor (TNF) family. Its binding with its receptor induces apoptosis. Fas ligand/receptor interactions play an important role in the regulation of the immune system and the progression of cancer. Mature human Fas Ligand consists of a 179 amino acid (aa) extracellular domain (ECD), a 22 aa transmembrane segment, and a 80 aa cytoplasmic domain. Within the ECD, human Fas Ligand shares 81% and 78% aa sequence identity with mouse and rat Fas Ligand, respectively. Apoptosis triggered by Fas-Fas ligand binding plays a fundamental role in the regulation of the immune system. Its functions include:T-cell homeostasis, cytotoxic T-cell activity, immune privilege, maternal tolerance, tumor counterattack. Defective Fas-mediated apoptosis may lead to oncogenesis as well as drug resistance in existing tumors. Germline mutation of Fas is associated with autoimmune lymphoproliferative syndrome (ALPS), a childhood disorder of apoptosis.[1-3]
||Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization.
||Fas Ligand, Heavy Labeled, fused with 6×His tag at the N-terminus, has a calculated MW of 17.7 kDa. The predicted N-terminus is Pro 134 . DTT-reduced Protein migrates as 25-32 kDa due to glycosylation.
||Less than 1.0 EU per μg of the Fas Ligand, Heavy Labeled by the LAL method.
||>95% as determined by SDS-PAGE.
||Avoid repeated freeze-thaw cycles.No activity loss was observed after storage at:In lyophilized state for 1 year (4oC-8oC); After reconstitution under sterile conditions for 1 month (4oC-8oC) or 3 months (-20oC to -70oC).